Discovering Breakthrough Cancer Therapies With Our Powerful Proprietary OGAP®-Verify Platform

There are 20,000 protein coding genes of which 95% undergo alternative splicing, resulting in 100,000 splice variants. OBT’s proprietary OGAP®-Splice, one of the world's largest cancer-specific protein expression splice variant databases, is revolutionising oncology target discovery. Using Artificial Intelligence (AI) and Machine Learning (ML), OGAP®-Splice identifies novel, cell surface-expressed splice variants, offering an entirely new class of targets for antibody-based therapeutics. Our unique platform is advancing the development of first-in-class therapies and supporting key industry partnerships. Notably, a new cancer-specific splice variant, is in preclinical development through our collaboration with Boehringer Ingelheim. OGAP®-Splice is set to launch as a fully validated platform within the next 12 months, expanding its capabilities to further accelerate target discovery and therapeutic development.